TY - JOUR
T1 - Associations between daily-living physical activity and laboratory-based assessments of motor severity in patients with falls and Parkinson's disease
AU - Galperin, Irina
AU - Hillel, Inbar
AU - Del Din, Silvia
AU - Bekkers, Esther M.J.
AU - Nieuwboer, Alice
AU - Abbruzzese, Giovanni
AU - Avanzino, Laura
AU - Nieuwhof, Freek
AU - Bloem, Bastiaan R.
AU - Rochester, Lynn
AU - Della Croce, Ugo
AU - Cereatti, Andrea
AU - Giladi, Nir
AU - Mirelman, Anat
AU - Hausdorff, Jeffrey M.
N1 - Funding Information:
We thank the study participants and all of those who contributed to the V-TIME project. This work was funded in part by a grant from the European Commission .
Funding Information:
Esther M.J. Bekkers and Alice Nieuwboer confirmed that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome. They acknowledge for partial funding of this project through a grant from Research Foundation Flanders (FWO) [grant number G.0867.15 ].
Funding Information:
Lynn Rochester reports grants from Medical Research Council, grants from EU, grants from NIHR, grants from Wellcome, grants from EPSRC, grants from Parkinson's UK, grants from Stroke Association in the last 36 months outside the submitted work.Bastiaan R. Bloem has declared that he received consultant services from Zambon and UCB. His grants/research support are: Netherlands Organisation for Scientific Research, Princess Beatrix Foundation, Michael J Fox Foundation, Parkinson Vereniging, National Parkinson Foundation, Hersenstichting Nederland, UCB, and AbbVie. He has received fees for speaking at conferences from AbbVie, Zambon, Biall.Esther M.J. Bekkers and Alice Nieuwboer confirmed that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome. They acknowledge for partial funding of this project through a grant from Research Foundation Flanders (FWO) [grant number G.0867.15].Nir Giladi reports that he is a consultant for: Neuroderm, Intec Pharma, Teva, Genzyme-Sanofi, Biogen, Lysosomal Therapeutics, Denali, Cellanis, GaitBetter, Vibrant and Sionara; that he holds shares or options in Lysosomal Therapeutics, Cellanis, GaitBetter and Vibrant; that he has received royalties from Lysosomal Therapeutics; that he received honorarium from UCB, Teva, Novartis, Abbvie, Genzyme-Sanofie, Neuroderm, Bial, Shire, MDS; that he have chaired the DSMBs for Teva and Pharma2B; that he is a PI on a Center Grant given by Biogen to TLVMC; that he has submitted a patent application on the use of body-fixed sensors for assessing PD symptoms, the intellectual property rights for which are held by the Tel Aviv Medical Center, and that he received grants from Teva, Biogen, LTI, ISF, EU, NIH, MJFF, Parkinson Foundation, and Pfizer.We thank the study participants and all of those who contributed to the V-TIME project. This work was funded in part by a grant from the European Commission.
Funding Information:
Lynn Rochester reports grants from Medical Research Council , grants from EU , grants from NIHR , grants from Wellcome, grants from EPSRC , grants from Parkinson's UK , grants from Stroke Association in the last 36 months outside the submitted work.
Publisher Copyright:
© 2019 Elsevier Ltd
PY - 2019/5/1
Y1 - 2019/5/1
N2 - Introduction: Recent work suggests that wearables can augment conventional measures of Parkinson's disease (PD). We evaluated the relationship between conventional measures of disease and motor severity (e.g., MDS-UPDRS part III), laboratory-based measures of gait and balance, and daily-living physical activity measures in patients with PD. Methods: Data from 125 patients (age: 71.7 ± 6.5 years, Hoehn and Yahr: 1–3, 60.5% men) were analyzed. The MDS-UPDRS-part III was used as the gold standard of motor symptom severity. Gait and balance were quantified in the laboratory. Daily-living gait and physical activity metrics were extracted from an accelerometer worn on the lower back for 7 days. Results: In multivariate analyses, daily-living physical activity and gait metrics, laboratory-based balance, demographics and subject characteristics together explained 46% of the variance in MDS-UPDRS-part III scores. Daily-living measures accounted for 62% of the explained variance, laboratory measures 30%, and demographics and subject characteristics 7% of the explained variance. Conversely, demographics and subject characteristics, laboratory-based measures of gait symmetry, and motor symptom severity together explained less than 30% of the variance in total daily-living physical activity. MDS-UPDRS-part III scores accounted for 13% of the explained variance, i.e., <4% of all the variance in total daily-living activity. Conclusions: Our findings suggest that conventional measures of motor symptom severity do not strongly reflect daily-living activity and that daily-living measures apparently provide important information that is not captured in a conventional one-time, laboratory assessment of gait, balance or the MDS-UPDRS. To provide a more complete evaluation, wearable devices should be considered.
AB - Introduction: Recent work suggests that wearables can augment conventional measures of Parkinson's disease (PD). We evaluated the relationship between conventional measures of disease and motor severity (e.g., MDS-UPDRS part III), laboratory-based measures of gait and balance, and daily-living physical activity measures in patients with PD. Methods: Data from 125 patients (age: 71.7 ± 6.5 years, Hoehn and Yahr: 1–3, 60.5% men) were analyzed. The MDS-UPDRS-part III was used as the gold standard of motor symptom severity. Gait and balance were quantified in the laboratory. Daily-living gait and physical activity metrics were extracted from an accelerometer worn on the lower back for 7 days. Results: In multivariate analyses, daily-living physical activity and gait metrics, laboratory-based balance, demographics and subject characteristics together explained 46% of the variance in MDS-UPDRS-part III scores. Daily-living measures accounted for 62% of the explained variance, laboratory measures 30%, and demographics and subject characteristics 7% of the explained variance. Conversely, demographics and subject characteristics, laboratory-based measures of gait symmetry, and motor symptom severity together explained less than 30% of the variance in total daily-living physical activity. MDS-UPDRS-part III scores accounted for 13% of the explained variance, i.e., <4% of all the variance in total daily-living activity. Conclusions: Our findings suggest that conventional measures of motor symptom severity do not strongly reflect daily-living activity and that daily-living measures apparently provide important information that is not captured in a conventional one-time, laboratory assessment of gait, balance or the MDS-UPDRS. To provide a more complete evaluation, wearable devices should be considered.
KW - Accelerometers
KW - Daily-living activity
KW - Digital health
KW - Inertial measurement units
KW - Parkinson's disease
KW - Wearable device
UR - http://www.scopus.com/inward/record.url?scp=85060892679&partnerID=8YFLogxK
U2 - 10.1016/j.parkreldis.2019.01.022
DO - 10.1016/j.parkreldis.2019.01.022
M3 - Article
C2 - 30718220
AN - SCOPUS:85060892679
VL - 62
SP - 85
EP - 90
JO - Parkinsonism and Related Disorders
JF - Parkinsonism and Related Disorders
SN - 1353-8020
ER -